Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2017-10-16 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
关于对外投资的公告（一）
Capital/Financing Update Classification · 95% confidence The document is an announcement by 嘉事堂药业股份有限公司 regarding an external investment to acquire 51% equity in 浙江同瀚生物技术有限公司. It details the transaction structure, shareholding changes, investment purpose, funding source, risks, and approvals. The document is a formal public announcement of a capital investment transaction, specifically an acquisition of shares in another company. It does not contain financial statements or detailed financial performance data, nor is it a report or transcript. It is not a full annual or interim report, nor an earnings release. It is not a regulatory filing or certification. The content fits best under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through acquisition of equity in another company. The document length is 3711 characters, which is consistent with an announcement rather than a full report.
2017-10-16 Chinese
关于第五届董事会第十九次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 19th meeting of the 5th Board of Directors of 嘉事堂药业股份有限公司. It details the approval of investment proposals to acquire controlling stakes in two companies. The document includes voting results and references to related announcements published elsewhere. It does not contain financial statements, audit opinions, or detailed financial data. It is a formal disclosure of board decisions, specifically about investments, and not a full report or financial filing. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2017-10-16 Chinese
关于对外投资的公告（二）
Capital/Financing Update Classification · 95% confidence The document is an announcement by 嘉事堂药业股份有限公司 regarding an external investment to acquire 51% equity in 浙江嘉事商漾医疗科技有限公司. It details the transaction structure, shareholding changes, investment purpose, funding source, and risks. The document is a formal public announcement of a capital investment transaction, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but focuses on the investment transaction and related corporate actions. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is 3752 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2017-10-16 Chinese
第五届董事会第十八次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolutions passed at the 18th meeting of the 5th Board of Directors of 嘉事堂药业股份有限公司. It mentions the approval of the 2017 semi-annual report and a special report on the use of raised funds, but it does not contain the actual reports or detailed financial data. Instead, it provides links and references to where the full reports can be found. The document is short (969 characters) and serves as a formal notice of board decisions rather than the report itself. According to the 'Menu vs Meal' rule, this type of document is classified as a Regulatory Filing (RNS) because it announces the approval and availability of reports but does not include the reports themselves.
2017-08-09 Chinese
第五届监事会第十三次会议决议的公告
Report Publication Announcement Classification · 95% confidence The document is an announcement of the supervisory board meeting resolution approving the company's 2017 semi-annual report and its summary. It states that the full semi-annual report and summary are published elsewhere with references to their announcement numbers and publication dates. The document itself does not contain the actual financial statements or substantive financial data but rather certifies the approval and authenticity of the report. The document length is short (807 characters) and it primarily serves as a notice of the meeting resolution and report approval, not the report itself. According to the MENU VS MEAL RULE and CERTIFICATION RULE, this is a Report Publication Announcement (RPA) rather than the Interim/Quarterly Report (IR) itself.
2017-08-09 Chinese
2017年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '嘉事堂药业股份有限公司 2017 年半年度财务报告' which translates to 'Jia Shi Tang Pharmaceutical Co., Ltd. 2017 Semi-Annual Financial Report'. It includes detailed financial statements such as consolidated balance sheets, profit statements, cash flow statements, and notes on accounting policies and estimates. The presence of comprehensive financial data for a half-year period and the explicit mention of '半年度财务报告' (semi-annual financial report) clearly indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial statements and analysis, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2017
2017-08-09 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.